However, in the context of cancer vaccination, these precursor populations are relatively rare, so developing agonists of CD40 that can serve as adjuvants for vaccines is a promising pathway to promote both CD4+ and CD8 T cell responses following vaccination. This evidence concerns the gene CD8A and cancer.